Caricamento...
PROTAC Technology: Opportunities and Challenges
[Image: see text] PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer...
Salvato in:
| Pubblicato in: | ACS Med Chem Lett |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Chemical
Society
2020
|
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7073876/ https://ncbi.nlm.nih.gov/pubmed/32184950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00597 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|